Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Invokana 100 substitute?

See the DrugPatentWatch profile for Invokana

Invokana is a brand-name medication containing the active ingredient canagliflozin. It is prescribed to manage type 2 diabetes by improving blood sugar control [1]. If you are looking for a substitute for Invokana, you might be interested in medications with the same active ingredient or those that work through similar mechanisms to treat type 2 diabetes.

What is Invokana prescribed for?


Invokana is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes [1]. It may also be used to reduce the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease [2]. Additionally, it is prescribed to reduce the risk of end-stage kidney disease, worsening of kidney disease, cardiovascular death, and hospitalization due to heart failure in patients with type 2 diabetes and diabetic nephropathy [3].

Can I get a generic version of Invokana?


As of December 2023, there is no generic version of Invokana available in the United States [4]. Drug patent expiration dates determine when generic versions can be manufactured and sold. Information on patent statuses and expected generic entry can be found on resources like DrugPatentWatch.com [5].

What other medications work like Invokana?


Invokana belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors [1]. These medications work by preventing the kidneys from reabsorbing sugar back into the blood, causing excess sugar to be removed from the body through urine [1]. Other SGLT2 inhibitors available include:

* Jardiance (empagliflozin) [6]
* Farxiga (dapagliflozin) [7]
* Steglatro (ertugliflozin) [8]

These medications are also prescribed for type 2 diabetes management and may have similar benefits and risks to Invokana [6, 7, 8].

How do SGLT2 inhibitors compare to other diabetes medications?


SGLT2 inhibitors offer a different mechanism of action compared to other common diabetes medications. For example, metformin, a first-line treatment for type 2 diabetes, primarily works by reducing glucose production by the liver and improving insulin sensitivity [9]. Other classes, like DPP-4 inhibitors or GLP-1 receptor agonists, also have distinct mechanisms for lowering blood sugar [10, 11]. The choice of medication depends on individual patient factors, including blood sugar levels, presence of other health conditions like heart disease or kidney disease, and potential side effects [9, 10, 11].

What are the potential side effects of Invokana?


Common side effects of Invokana include yeast infections of the vagina and urinary tract infections [1]. More serious, though less common, side effects can include ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones [1]. Invokana also carries a risk of lower limb amputations, though the exact cause is not fully understood [1].

Where can I find more information about Invokana's patents?


Information regarding Invokana's patent status, including any challenges or expiration dates, is publicly available. Resources like DrugPatentWatch.com track these details, which can be crucial for understanding when generic alternatives might become available [5].

---

Sources:

[1] Invokana Prescribing Information
[2] Invokana: Cardiovascular Risk Reduction Data
[3] Invokana: Kidney Disease Data
[4] Generic Invokana Status (as of December 2023)
[5] DrugPatentWatch.com
[6] Jardiance Prescribing Information
[7] Farxiga Prescribing Information
[8] Steglatro Prescribing Information
[9] Metformin Information
[10] DPP-4 Inhibitors Information
[11] GLP-1 Receptor Agonists Information



Other Questions About Invokana :

invokana online pharmacy Is there a generic for invokana? Invokana date of patent expiry? Invokana duo?

AI-Drug Label Prescribing Information Alignment Report

56
56%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

Several core label-consistent claims are present (active ingredient, SGLT2 class mechanism, and major indication-risk statements). However, multiple claims are not supported by the provided FDA label text, including comparator drugs (Jardiance/Farxiga/Steglatro), external patent/generic-market assertions, and specific “common side effects” and ketoacidosis definition/etiology statements.


Category Scores

Indication
86
Good
Dosage
0
Partial
Warnings
55
Partial
AdverseReactions
45
Partial

Accurate Statements

Invokana is a brand-name medication containing the active ingredient canagliflozin.
11 DESCRIPTION
Invokana is prescribed to manage type 2 diabetes by improving blood sugar control.
1 INDICATIONS AND USAGE
Invokana is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
1 INDICATIONS AND USAGE
Invokana belongs to the class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
11 DESCRIPTION
SGLT2 inhibitors work by preventing the kidneys from reabsorbing sugar back into the blood.
11 DESCRIPTION (SGLT2 transporter responsible for reabsorbing filtered glucose)
SGLT2 inhibitors cause excess sugar to be removed from the body through urine.
7 DRUG INTERACTIONS (Positive urine glucose test; increased urinary glucose excretion)
Invokana can cause ketoacidosis.
6 ADVERSE REACTIONS (Diabetic Ketoacidosis... [Warnings and Precautions reference])
Invokana carries a risk of lower limb amputations.
6 ADVERSE REACTIONS (Lower Limb Amputation)
Invokana may reduce the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.
1 INDICATIONS AND USAGE (reduction of major adverse cardiovascular events: cardiovascular death, nonfatal MI, nonfatal stroke in adults with established CVD)
Invokana is prescribed to reduce the risk of end-stage kidney disease in patients with type 2 diabetes and diabetic nephropathy.
1 INDICATIONS AND USAGE (reduce risk of end-stage kidney disease)
Invokana is prescribed to reduce the risk of cardiovascular death in patients with type 2 diabetes and diabetic nephropathy.
1 INDICATIONS AND USAGE (reduce risk of CV death)
Invokana is prescribed to reduce the risk of hospitalization due to heart failure in patients with type 2 diabetes and diabetic nephropathy.
1 INDICATIONS AND USAGE (hospitalization for heart failure)

Unsupported Statements

As of December 2023, there is no generic version of Invokana available in the United States.
Not supported by the provided FDA label sections (external market/generic-status statement not present).
Jardiance is an SGLT2 inhibitor (empagliflozin).
Provided FDA label excerpt is for Invokana only; no information about Jardiance in the supplied label sections.
Farxiga is an SGLT2 inhibitor (dapagliflozin).
Provided FDA label excerpt is for Invokana only; no information about Farxiga in the supplied label sections.
Steglatro is an SGLT2 inhibitor (ertugliflozin).
Provided FDA label excerpt is for Invokana only; no information about Steglatro in the supplied label sections.
Jardiance, Farxiga, and Steglatro are prescribed for type 2 diabetes management.
No such cross-product prescribing claims are present in the provided Invokana label sections.
Jardiance, Farxiga, and Steglatro may have similar benefits and risks to Invokana.
The provided Invokana label does not provide comparative benefits/risks across other products.
Common side effects of Invokana include yeast infections of the vagina.
The provided label excerpt lists genitourinary infections as important adverse reactions, but does not provide the claim framed as “common side effects” nor the specific “yeast infections of the vagina” side-effect frequency wording.
Common side effects of Invokana include urinary tract infections.
The provided label excerpt references genitourinary infections including urosepsis/pyelonephritis, but does not provide the claim framed as “common side effects” or a specific “urinary tract infections” common-side-effect statement.
Ketoacidosis is described as a serious condition where the body produces high levels of blood acids called ketones.
The provided label excerpt references ketoacidosis as an adverse reaction but does not include this definition/description.
The exact cause of Invokana-related lower limb amputations is not fully understood.
No causation/knowledge statement about lower limb amputations appears in the provided label excerpt.
Information regarding Invokana's patent status, including challenges or expiration dates, is publicly available.
Not supported by the provided FDA label sections (external patent-status statement not present).
Resources like DrugPatentWatch.com track Invokana patent details.
External resource claim not supported by the provided FDA label sections.

Contradictions

Low

AI Statement
Invokana is prescribed to reduce the risk of worsening of kidney disease in patients with type 2 diabetes and diabetic nephropathy.

Label Reference
1 INDICATIONS AND USAGE


Important Omissions

No dosage and administration details were provided in the AI claims, despite being part of the requested label alignment dimensions.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Unsupported external and comparator statements do not directly change Invokana-specific safety instructions. However, “common side effects” claims and an imprecise kidney-outcome wording are not substantiated by the provided label excerpts; these could mislead interpretation of frequency or endpoint framing.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Mostly Aligned

Primary Issue
Multiple statements are not supported by the provided Invokana FDA label excerpt, including comparator-brand/class details, “common side effects” frequency framing, ketoacidosis definition, and external patent/generic assertions.

Suggested Improvement
Limit claims to the provided label-supported Invokana content (indications and listed important adverse reactions) and remove/avoid external market/patent and other-brand comparative assertions unless corresponding FDA-label sections are provided.

Drug Brand Mention Assessment

Branding Score
66
Visibility
66
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
strong alternative
Brand Perception
Best Known For

manage type 2 diabetes by improving blood sugar control


Core Claims
  • Invokana is a brand-name medication containing canagliflozin.
  • It is prescribed to manage type 2 diabetes by improving blood sugar control.
  • It is used to lower blood sugar in adults with type 2 diabetes.
  • It may reduce the risk of major cardiovascular events in adults with type 2 diabetes with known cardiovascular disease.
  • It may reduce the risk of end-stage kidney disease and hospitalization due to heart failure in certain patients.
Differentiators
  • It belongs to the class of SGLT2 inhibitors.
  • It works by preventing the kidneys from reabsorbing sugar back into the blood.

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Boehringer Ingelheim 6%
50 #4 No
AstraZeneca 6%
50 #3 No
Eli Lilly and Company 6%
50 #2 No
Merck & Co. 6%
50 #5 No